Literature DB >> 2790192

Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: type-specific identification of HTLVs by polymerase chain reaction.

G D Ehrlich1, J B Glaser, K LaVigne, D Quan, D Mildvan, J J Sninsky, S Kwok, L Papsidero, B J Poiesz.   

Abstract

The extent of human T-cell leukemia/lymphoma virus type II (HTLV-II) infection and its rate of spread have been difficult to determine owing to the serological cross-reactivity between HTLV-I and HTLV-II. The present study overcame this problem by directly detecting type-specific proviral sequences by means of the polymerase chain reaction (PCR) and liquid hybridization. Screening was performed on a cohort of primarily white intravenous drug abusers (IVDAs), and individuals of other behaviorally defined risk groups from the New York City area. Eleven percent (19 of 169) of the individuals in these high-risk groups were determined by PCR to have HTLV-II proviral infections. One of these patients displayed an exfoliative erythrodermatitis. Thirteen of the 19 subjects were positive in an HTLV-II enzyme-linked immunosorbent assay (ELISA). The remaining six individuals, although negative in the HTLV-II ELISA, were confirmed as HTLV-II positive by analyzing their DNA with a second HTLV-II-specific primer detector system. Four additional individuals were reactive in the HTLV-II ELISA but were PCR-negative for HTLV-II. PCR analysis for HTLV-I revealed that all four were positive for that virus. Thirty-seven percent (seven of 19) of the HTLV-II PCR-positive subjects were also PCR-positive for HTLV-I, and 84% (16 of 19) of the HTLV-II positive individuals were infected with human immunodeficiency virus (HIV-1). Six individuals were triply infected with HTLV-I, HTLV-II, and HIV-1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790192

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk.

Authors:  F J Medrano; V Soriano; E J Calderón; C Rey; M Gutiérrez; R Bravo; M Leal; J González-Lahoz; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

2.  Polymerase chain reaction (PCR) amplification demonstrates the absence of human T-cell lymphotrophic virus (HTLV)-I specific pol sequences in peripheral T-cell lymphomas.

Authors:  T Henni; M Divine; P Gaulard; C Haioun; M Duc Dodon; M F Gourdin; L Desforges; M Goossens; F Reyes; J P Farcet
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

3.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

4.  Sensitive and specific polymerase chain reaction assays for diagnosis of human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infections in HTLV-I/II-seropositive individuals.

Authors:  W Heneine; R F Khabbaz; R B Lal; J E Kaplan
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

5.  Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I.

Authors:  N Fan; J Gavalchin; B Paul; K H Wells; M J Lane; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

6.  Immunodetection of human T-cell lymphotropic virus type I core protein in biological samples by using a monoclonal antibody immunoassay.

Authors:  L Papsidero; F Swartzwelder; M Sheu; R Montagna; G Ehrlich; S Bhagavati; H Dosik; J Sninsky; B Poiesz
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

7.  The inability of human immunodeficiency virus to infect chimpanzee monocytes can be overcome by serial viral passage in vivo.

Authors:  H E Gendelman; G D Ehrlich; L M Baca; S Conley; J Ribas; D C Kalter; M S Meltzer; B J Poiesz; P Nara
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

8.  Prevalence of HTLV-II in HIV-1-infected drug addicts in Marseille.

Authors:  C Vignoli; C Zandotti; X De Lamballerie; C Tamalet; J A Gastaut; P De Micco
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

9.  Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus types I and II.

Authors:  B D Roberts; S K Foung; J J Lipka; J E Kaplan; K G Hadlock; G R Reyes; L Chan; W Heneine; R F Khabbaz
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

10.  Genetic heterogeneity in human T-cell leukemia/lymphoma virus type II.

Authors:  D K Dube; M P Sherman; N K Saksena; V Bryz-Gornia; J Mendelson; J Love; C B Arnold; T Spicer; S Dube; J B Glaser
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.